Journal profile · Oncology
Expert Review of Anticancer Therapy
ISSN 1473-7140 · eISSN 1744-8328 · Taylor and Francis Ltd. · ENGLAND · Bimonthly · Founded 2001
Expert Review of Anticancer Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.09; subscription journal; median 76 days to acceptance (99 articles, last 24 months); community-reported acceptance: easy; 187 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Review of Anticancer Therapy is published by Taylor and Francis Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers and Bladder and Urothelial Cancer Treatments, together about 18.6% of its articles. Its main subfields are Oncology and Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
Source: LetPub
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Treatments and MutationsMedicine7.1%
- Cancer Immunotherapy and BiomarkersMedicine6.1%
- Bladder and Urothelial Cancer TreatmentsMedicine5.4%
- Renal cell carcinoma treatmentMedicine5.1%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5%
- Prostate Cancer Treatment and ResearchMedicine4.8%
- Lung Cancer Research StudiesMedicine4.7%
- HER2/EGFR in Cancer ResearchMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.09LetPub ·
- CiteScore 2026-06
- 4.9LetPub ·
- SJR 2026-06
- 0.84LetPub ·
- SNIP 2026-06
- 0.7LetPub ·
- h-index
- 59LetPub ·
- h-index
- 99OpenAlex ·
- i10-index
- 1,953OpenAlex ·
- 2-year mean citedness
- 2.87OpenAlex ·
- Self-citation rate
- 3.3%LetPub ·
- Share of gold OA articles
- 2.11%LetPub ·
Volume
- Articles per year
- 164LetPub ·
Articles by year OpenAlex count · 3,765 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 94 | 23 | 37 |
| 2025 | 187 | 31 | 479 |
| 2024 | 118 | 31 | 630 |
| 2023 | 115 | 27 | 1,118 |
| 2022 | 117 | 31 | 1,165 |
| 2021 | 104 | 26 | 1,518 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
76 daysMedian, submission to acceptance · P25–P75 52 days – 109 days
- Acceptance to online
- median 9 days (99 articles)
- Submission to online
- median 85 days
- Sample
- 99 articles with submission and acceptance dates (308 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2001
- ISSN
- 1473-7140
- Electronic ISSN
- 1744-8328
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Expert Review of Anticancer Therapy
What CAS zone is Expert Review of Anticancer Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Review of Anticancer Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Review of Anticancer Therapy?
The latest impact factor listed by LetPub is 3.09; CiteScore 4.9, h-index 99.
How long does peer review take at Expert Review of Anticancer Therapy?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 76 days (interquartile range 52–109 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Review of Anticancer Therapy?
According to LetPub and DOAJ records, Expert Review of Anticancer Therapy is indexed in SCIE and Scopus.
Is Expert Review of Anticancer Therapy open access, and what is the APC?
Expert Review of Anticancer Therapy is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .